Finding the right job for the tool: Alemtuzumab and its role in renal transplantation

American Journal of Transplantation

Volumn 8, Issue 7, 2008, Pages 1363-1364

  Newell, K A ^a   Cendales, L C ^a   Kirk, A D ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; ALLOANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

EDITORIAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 47249161546     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02291.x     Document Type: Editorial

References (14)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4: 378 383.
2. Curtis JJ, Kaplan B. Transplant immunosuppressive drug trials on trial. Am J Transplant 2004 4: 671 672.
3. Fritsche L, Einecke G, Fleiner F, Dragun D, Neumayer HH, Budde K. Reports of large immunosuppression trials in kidney transplantation: Room for improvement. Am J Transplant 2004 4: 738 743.
4. Pascual J, Pirsch J, Torrealba J et al. Antibody-mediated rejection (AMR) in renal transplant recipients treated with alemtuzumab induction. Am Transplant Congress. Toronto, 2008.
5. Calne R, Moffatt SD, Friend PJ et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999 68: 1613 1616.
6. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005 5: 1347 1353.
7. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 76: 120 129.
8. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005 80: 1051 1059.
9. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005 5: 3009 3014.
10. Knechtle SJ, Pirsch JD, H. Fechner JJ et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 3: 722 730.
11. Gruessner RW, Kandaswamy R, Humar A, Gruessner AC, Sutherland DE. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005 79: 1184 1189.
12. Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006 6: 2409 2417.
13. Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004 78: 426 433.
14. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008 22: 200 210.